Khaled Hani Aburisheh

Dr. Khaled Hani Aburisheh

University Diabetes Center, King Saud University Medical City, King Saud University, Riyadh, Ar Riyāḑ, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
IAIman S Algadi
Iman S Algadi
YAYazed AlRuthia
Yazed AlRuthia
MMMuhammad Hussain Mujammami
Muhammad Hussain Mujammami
Khaled Hani AburishehKhaled Hani Aburisheh
Khaled Hani Aburisheh
MAMetib Alotaibi
Metib Alotaibi
DKDr.Reem Al Khalifah
Dr.Reem Al Khalifah
Background: Type 1 diabetes (T1D) is a growing global health concern, with a notable rise in incidence in Saudi Arabia. Despite the potential benefits of early detection through screening programs, such initiatives are currently lacking in Saudi Arabia and other Arab countries. Objective: This study aims to evaluate the feasibility, acceptability, and cost-effectiveness of a T1D-screening program targeting high-risk individuals, specifically children with a first-degree relative diagnosed with T1D. Methods: The VISION-T1D program is a prospective cohort study focused on the early detection of presymptomatic T1D by screening children aged 2-18 years. The primary screening method involves testing for islet autoantibodies, including insulin autoantibodies, glutamic acid decarboxylase autoantibodies, insulinoma associated-2 autoantibodies, and zinc transporter-8 autoantibodies. Optional genetic testing, including human leukocyte antigen phenotyping and the genetic risk score, is offered. Outcomes include the feasibility of the screening process, prevalence of early-stage T1D, psychological impacts, educational intervention effectiveness, progression rates to stage-3 T1D, and economic viability. Results: The VISION-T1D program began in May 2024. As of December 2024, a total of 176 families have been enrolled. Data collection will continue until April 2025, with final data analysis projected for mid-2025. Conclusions: The VISION-T1D study provides a practical approach to T1D screening tailored to the health care landscape of Saudi Arabia. The insights gained from this pilot program will inform the development of a national, population-based screening initiative designed to reduce diabetic ketoacidosis at diagnosis, improve long-term outcomes, and alleviate the economic burden of T1D. The VISION-T1D initiative could also serve as a scalable and sustainable model that can be adopted internationally, contributing to global efforts to manage and prevent T1D. Trial Registration: ClinicalTrials.gov NCT06513247; https://clinicaltrials.gov/study/NCT06513247 International Registered Report Identifier (IRRID): DERR1-10.2196/70575

7 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Khaled Hani AburishehKhaled Hani Aburisheh
Khaled Hani Aburisheh
MBMazen Mahmoud Barhoush
Mazen Mahmoud Barhoush
AAAbdulaziz N. Alahmari
Abdulaziz N. Alahmari
ZAZiyad Ali Altasan
Ziyad Ali Altasan
MAMuffarah H. Alharthi
Muffarah H. Alharthi
Background: Gestational diabetes mellitus (GDM) is a common endocrine disease that can occur during pregnancy, increasing the risk of fetal morbidity and mortality. Metformin is a commonly used therapeutic approach for managing GDM. However, there is controversy regarding the effects of metformin on fetal outcomes during pregnancy. This study aimed to evaluate the safety of metformin in relation to neonatal complications, compared to treatment with insulin and/or specialized diets. Method: This was a retrospective study that included pregnant women who were diagnosed with GDM and treated with specialized diets, metformin, or insulin. Data were collected from patients’ electronic medical records and analyzed to evaluate the risk of neonatal outcomes in the metformin group compared to the others. Results: The study included 234 women with GDM. There was no difference between the metformin and insulin groups in terms of the rates of neonatal outcomes, while neonatal hypoglycemia, neonatal hyperbilirubinemia, large for gestational age, and respiratory distress were higher in the metformin group when compared to the diet group. Metformin slightly increased the risk of a lower APGAR score compared to diet alone. Conclusions: Metformin was found to be a safe therapy for the fetus when used to manage GDM, compared to insulin therapy. More randomized studies are needed to confirm these findings in the Saudi population.

AAAbdulaziz A. Alhoqail
Abdulaziz A. Alhoqail
Khaled Hani AburishehKhaled Hani Aburisheh
Khaled Hani Aburisheh
AAAbdulrahman M. Alammar
Abdulrahman M. Alammar
MMMohammed Abdulaziz Bin Mugren
Mohammed Abdulaziz Bin Mugren
ASAbdulrahman Shadid
Abdulrahman Shadid
FAfaisal alotaibi
faisal alotaibi
Background: Poor sleep quality is prevalent among adults with diabetes, impacting their physical, psychological, and functional well-being. Our goals were to assess the prevalence of poor sleep quality and its association with glycemic control and to identify predictors of poor sleep quality among adults with diabetes mellitus. Methods: This cross-sectional study took place at a tertiary hospital, from October 2022 to March 2023, including 192 adults with type 1 and type 2 diabetes. We collected demographic and clinical data and utilized the Pittsburgh Sleep Quality Index (PSQI) scale to evaluate sleep quality. Results: A total of 65.9% of the participants experienced poor sleep quality (PSQI score > 5), with an average global sleep quality score of 7.36 ± 3.53 for all patients. Poor sleep quality was higher among older and married patients, those with lower education levels, housewives, and those with type 2 diabetes mellitus and associated comorbidities, such as hypertension and dyslipidemia. None of these factors were significantly associated with sleep quality in a multiple linear regression analysis. The mean glycated hemoglobin was 8.68 ± 1.91% and did not correlate with the overall PSQI score and its components. Conclusions: This study revealed a notably high prevalence of poor sleep quality among Saudi adults with diabetes, potentially associated with specific sociodemographic and clinical factors. These findings emphasize the importance of integrating sleep quality education into diabetes management strategies.

16 November 2023 in Biology
Verified
Journal Article
Open access
PDF file
ZAZeina Alkudmani
Zeina Alkudmani
AAAminah Ahmad Alzailai
Aminah Ahmad Alzailai
Khaled Hani AburishehKhaled Hani Aburisheh
Khaled Hani Aburisheh
AAAmal F. Alshammary
Amal F. Alshammary
Imran Ali KhanImran Ali Khan
Imran Ali Khan
Diabetes mellitus is a complex disease with a wide range of manifestations. Diabetes, notably type 2 diabetes mellitus (T2DM), is becoming more common in Saudi Arabia as a result of obesity and an aging population. T2DM is classified as a noncommunicable disease, and its incidence in the Saudi population continues to grow as a consequence of socioeconomic changes. Toll-like receptors (TLRs) are innate immune receptors that mediate the inflammatory response in diabetes mellitus. Previous studies have documented the relationship between different SNPs in the TLR9 gene in different forms of diabetes. As a result, the purpose of this study was to investigate the relationship between rs187084, rs352140, and rs5743836 SNPs in the TLR9 gene among T2DM patients in the Saudi population. This was a case-control study that included 100 T2DM cases and 100 control subjects. The three SNPs were identified in the study population (n = 200) using polymerase chain reaction (PCR), restriction enzymes for rs352140, and Sanger sequencing for rs187084 and rs5783836. Next, statistical analyses were performed using various software to determine the association between the SNPs and T2DM. rs187084 and rs5743836 were associated with an increased risk of T2DM development. rs187084 and rs5743836 allelic frequencies were associated with a 3.2 times increased risk of T2DM development (p < 0.05). DBP was associated with T2DM (p = 0.02). rs187084 was associated with TC and HDLc; rs352140 was associated with DBP, HbA1c, and HDLc; rs5743836 was associated with waist (p < 0.05). The CGT haplotype was strongly associated with T2DM (p < 0.003). Gene–gene interaction, graphical presentation, and dendrogram showed the strong association with T2DM patients (p < 0.05). This study concluded that rs187084 and rs5743836 were strongly associated with T2DM in Saudi Arabian patients. This study provides further evidence that SNPs in the TLR9 gene play a significant role in T2DM development in a Saudi community.

1 November 2023 in Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
Khaled Hani AburishehKhaled Hani Aburisheh
Khaled Hani Aburisheh
MAMohammed Khalid Alkhalifah
Mohammed Khalid Alkhalifah
MAMohammad Fahad AlKheraiji
Mohammad Fahad AlKheraiji
SASaleh Ibrahim Alwalan
Saleh Ibrahim Alwalan
MAMohammed Jamal Anabi
Mohammed Jamal Anabi
AAAmani Ayyed Aldhewaila
Amani Ayyed Aldhewaila
Background: Coronavirus disease 2019 (COVID-19) affected the whole world socially, economically, and medically. People with diabetes mellitus could have higher rates of morbidity and mortality if infected by the virus. New-onset diabetes and diabetic emergencies were, in some cases, first identified after the COVID-19 vaccine. In this study, we aimed to evaluate the acute effect of COVID-19 vaccination on the glycemic parameters of patients with type 1 diabetes mellitus (T1DM). Methods: This was a retrospective observational study that included patients with T1DM older than 14 years old using Freestyle libre sensors and vaccinated with the COVID-19 vaccine. Data were collected from patients’ electronic medical records and glycemic profile parameters 1 to 2 weeks before and 1 to 2 weeks after the vaccine were extracted from the LibreView system. Results: Seventy-two vaccines were analyzed from 44 patients with T1DM. There was no acute change of interstitial glucose measures after COVID-19 vaccination; however, there was a significant reduction in time in range and an increase in time above range after vaccination in those who were aged above 28 and had longer duration and better diabetes mellitus (DM) control. Glycated hemoglobin (HbA1c) was the only independent factor associated with the change in the glycemic profile after vaccination in multivariate regression analysis. Conclusion: In our study population, there was no significant change in glycemic parameters after COVID-19 vaccination but those above 28 years old with longer duration of DM and lower HbA1c could have shifted upward their interstitial glucose levels. Precautions could be considered in those groups before receiving the vaccine. J Endocrinol Metab. 2023;13(4):144-152 doi: https://doi.org/10.14740/jem894

1 December 2024 in Journal of Medical Cases
Verified
Journal Article
Open access
PDF file
Khaled Hani AburishehKhaled Hani Aburisheh
Khaled Hani Aburisheh
HEHamza M.K. Enabi
Hamza M.K. Enabi
NANora A. Alodah
Nora A. Alodah
BABassam H. Alotary
Bassam H. Alotary
LALinah A. Algheryafi
Linah A. Algheryafi
AAAmani A. Aldhewaila
Amani A. Aldhewaila
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased morbidity and mortality worldwide. Coronavirus disease 2019 (COVID-19) vaccines have shown high efficacy in preventing the infection but with many possible side effects such as hyperglycemia. New-onset diabetes mellitus (DM) and severe metabolic complications have been reported post-vaccination. Here we report a 45-year-old woman who came to the hospital complaining of polyurea, polydipsia, and weight loss 3 weeks after the first activation dose of COVID-19 vaccine. Her hemoglobin A1c (HbA1c) upon presentation was 9% without any prior history of DM. She was diagnosed with type 1 diabetes mellitus (T1DM), as the anti-glutamic acid decarboxylase (GAD) antibody was positive and complicated during follow-up with diabetic ketoacidosis (DKA). This is the first case in Saudi Arabia suggesting that the COVID-19 RNA-based vaccines might cause new onset of T1DM, complicated by late DKA.